The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.

The latest price target for Galectin Therapeutics (NASDAQ: GALT) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting GALT to rise to within 12 months (a possible 472.92% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Galectin Therapeutics (NASDAQ: GALT) was provided by HC Wainwright & Co., and Galectin Therapeutics reiterated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galectin Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galectin Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

While ratings are subjective and will change, the latest Galectin Therapeutics (GALT) rating was a reiterated with a price target of $11.00 to $11.00. The current price Galectin Therapeutics (GALT) is trading at is $1.92, which is out of the analyst’s predicted range.